• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aminotoluenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes Aminotoluenes

Introduction to 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride (CAS No. 1143459-92-0)

The compound 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride, identified by its CAS number 1143459-92-0, represents a significant advancement in the field of pharmaceutical chemistry. This molecule, characterized by its intricate structural framework, has garnered considerable attention due to its potential applications in medicinal chemistry and drug discovery. The presence of multiple heterocyclic rings, including a thiazole and a pyridine moiety, combined with an aromatic diamine backbone, positions this compound as a versatile scaffold for developing novel therapeutic agents.

Recent studies have highlighted the importance of 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride in the design of molecules targeting various biological pathways. Its structural features suggest interactions with enzymes and receptors involved in inflammatory responses, making it a promising candidate for exploring treatments against chronic diseases such as arthritis and autoimmune disorders. The dihydrochloride salt form enhances solubility and bioavailability, which are critical factors in drug formulation and delivery.

In the realm of oncology research, this compound has been investigated for its potential to modulate signaling pathways associated with cancer cell proliferation. The thiazole and pyridine components are known to exhibit pharmacological activity by interfering with key enzymes like kinases and phosphodiesterases. Preliminary in vitro studies have demonstrated inhibitory effects on certain cancer-related targets, warranting further exploration in preclinical models. The benzene diamine core further contributes to the compound's binding affinity by forming hydrogen bonds and hydrophobic interactions with biological macromolecules.

The synthesis of 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including palladium-catalyzed cross-coupling reactions and nucleophilic substitutions, have been employed to construct the desired framework efficiently. The dihydrochloride salt formation is achieved through careful acidification and recrystallization processes, ensuring the compound's stability for subsequent biological evaluations.

From a computational chemistry perspective, molecular docking studies have been conducted to elucidate the binding mode of 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride with potential target proteins. These simulations have provided insights into key interaction points between the compound and its biological counterparts, guiding the optimization of lead structures for improved potency and selectivity. The integration of experimental data with computational predictions has become an indispensable approach in modern drug discovery pipelines.

The pharmacokinetic profile of this compound is another critical area of investigation. Studies have assessed its absorption, distribution, metabolism, and excretion (ADME) properties using relevant animal models. The dihydrochloride salt form demonstrates favorable solubility in aqueous media, facilitating oral administration and systemic distribution. Metabolic stability assessments have revealed that the compound undergoes limited degradation under physiological conditions, suggesting a prolonged half-life and sustained therapeutic effects.

Future directions in the research of 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride include exploring its role in neurodegenerative diseases such as Alzheimer's and Parkinson's. The structural motifs present in this molecule exhibit potential interactions with amyloid-beta plaques and tau protein aggregates, which are hallmark pathological features of these conditions. Preclinical trials are planned to evaluate its efficacy in animal models before human clinical studies can be initiated.

The impact of this compound extends beyond traditional pharmaceutical applications. Its unique structural composition makes it a valuable tool for chemists developing new synthetic methodologies and libraries of bioactive molecules. Collaborative efforts between academia and industry are fostering innovative approaches to harnessing the therapeutic potential of 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride, ensuring its integration into next-generation drug candidates.

In conclusion, 4-Methyl-n3-4-(3-pyridinyl)-2-thiazolyl-1,3-benzenediaminedihydrochloride (CAS No. 1143459-92-0) stands as a testament to the progress being made in medicinal chemistry through innovative molecular design. Its multifaceted applications across various therapeutic areas highlight its significance as a lead compound for future drug development. As research continues to uncover new biological targets and mechanisms, this molecule will undoubtedly play a pivotal role in advancing therapeutic strategies against some of the most challenging diseases faced by humanity today.

• 315703-20-9(Phenol, 4-[[4-(3-pyridinyl)-2-thiazolyl]amino]-)
• 5656-12-2(Benzonitrile,5-[bis(2-hydroxyethyl)amino]-2-[2-(2-chloro-4-nitrophenyl)diazenyl]-)
• 5746-80-5(N-[4-(pyridin-4-yl)-1,3-thiazol-2-yl]benzene-1,4-diamine)
• 315702-99-9(STF-62247)
• 1619-41-6(N1-(4-Phenylthiazol-2-yl)benzene-1,3-diamine)
• 5833-82-9(N-(2-methylphenyl)-4-(pyridin-3-yl)-1,3-thiazol-2-amine)
• 30162-42-6(3-Pyridinamine,N-[4-(3-pyridinyl)-2-thiazolyl]-)
• 1619-40-5(N1-(4-Phenylthiazol-2-yl)benzene-1,4-diamine)
• 1843-16-9(2-Thiazolamine,N,4-diphenyl-)
• 5642-88-6(N-(2,5-dimethylphenyl)-4-phenyl-1,3-thiazol-2-amine)